Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP

被引:211
作者
Gervais, FG [1 ]
Cruz, RPG [1 ]
Chateauneuf, A [1 ]
Gale, S [1 ]
Sawyer, N [1 ]
Nantel, F [1 ]
Metters, KM [1 ]
O'Neill, GP [1 ]
机构
[1] Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Kirkland, PQ H9R 4P8, Canada
关键词
eosinophils; G-protein-coupled receptor; receptors; CRTH2; DP; PGD(2); chemokinesis; degranulation; apoptosis;
D O I
10.1067/mai.2001.119919
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: PGD(2) is the major prostanoid released by mast cells during an allergic response. Its role in the allergic response, however, remains unclear. Objective: Because the accumulation of eosinophils is a feature of allergic reactions, we investigated the role of PGD(2) in the modulation of eosinophil function. Methods: Circulating human eosinophils were isolated and challenged with PGD(2). The effects of PGD(2) on various eosinophil functions were then analyzed. Results: PGD(2) binds with high affinity preferentially to 2 receptors, DP and chemoattractant receptor-homologous molecule expressed on T(H)2 cells (CRTH2). We show that both DP and CRTH2 are detectable on circulating eosinophils. We demonstrate that PGD(2) (1-10 nmol/L) induces a rapid change in human eosinophil morphology and an increase in chemokinesis and promotes eosinophil degranulation. These effects are induced by the CRTH2-selective agonist 13-14-dihydro-15-keto-PGD(2) (DK-PGD(2)) but not by the DP-selective agonist BW245C. These results suggest a role for CRTH2 in the modulation of eosinophil movement and in triggering the release of cytotoxic proteins. Finally, we demonstrate that BW245C, but not DK-PGD(2), can delay the onset of apoptosis in cultured eosinophils, presumably through interaction with DP. Conclusion: These data support the hypothesis that PGD(2) controls eosinophil functions through 2 pharmacologically distinct receptors with independent functions. Blockade of PGD(2)-mediated effects on human eosinophils may reduce the damage caused by these cells during an allergic response, but inhibition of both receptors may be required.
引用
收藏
页码:982 / 988
页数:7
相关论文
共 33 条
[1]   The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs [J].
Abramovitz, M ;
Adam, M ;
Boie, Y ;
Carrière, MC ;
Denis, D ;
Godbout, C ;
Lamontagne, S ;
Rochette, C ;
Sawyer, N ;
Tremblay, NM ;
Belley, M ;
Gallant, M ;
Dufresne, C ;
Gareau, Y ;
Ruel, R ;
Juteau, H ;
Labelle, M ;
Ouimet, N ;
Metters, KM .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1483 (02) :285-293
[2]  
ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393
[3]   EOSINOPHIL GRANULE PROTEINS IN PERIPHERAL-BLOOD GRANULOCYTES [J].
ABUGHAZALEH, RI ;
DUNNETTE, SL ;
LOEGERING, DA ;
CHECKEL, JL ;
KITA, H ;
THOMAS, LL ;
GLEICH, GJ .
JOURNAL OF LEUKOCYTE BIOLOGY, 1992, 52 (06) :611-618
[4]   MOLECULAR-CLONING AND CHARACTERIZATION OF THE HUMAN PROSTANOID DP RECEPTOR [J].
BOIE, Y ;
SAWYER, N ;
SLIPETZ, DM ;
METTERS, KM ;
ABRAMOVITZ, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (32) :18910-18916
[5]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
[6]   A SINGLE-STEP PURIFICATION OF BIOLOGICALLY-ACTIVE RECOMBINANT HUMAN INTERLEUKIN-5 FROM A BACULOVIRUS EXPRESSION SYSTEM [J].
BROWN, PM ;
SCHEID, MP ;
ONEIL, GP ;
TAGARI, PC ;
NICHOLSON, DW .
PROTEIN EXPRESSION AND PURIFICATION, 1995, 6 (01) :63-71
[7]  
CARLSON M, 1993, ALLERGY, V48, P437
[8]   Role of cAMP-dependent pathway in eosinophil apoptosis and survival [J].
Chang, HS ;
Jeon, KW ;
Kim, YH ;
Chung, IY ;
Park, CS .
CELLULAR IMMUNOLOGY, 2000, 203 (01) :29-38
[9]   FEATURES OF APOPTOTIC CELLS MEASURED BY FLOW-CYTOMETRY [J].
DARZYNKIEWICZ, Z ;
BRUNO, S ;
DELBINO, G ;
GORCZYCA, W ;
HOTZ, MA ;
LASSOTA, P ;
TRAGANOS, F .
CYTOMETRY, 1992, 13 (08) :795-808
[10]   PROSTAGLANDIN-D2 CAUSES ACCUMULATION OF EOSINOPHILS IN THE LUMEN OF THE DOG TRACHEA [J].
EMERY, DL ;
DJOKIC, TD ;
GRAF, PD ;
NADEL, JA .
JOURNAL OF APPLIED PHYSIOLOGY, 1989, 67 (03) :959-962